» Authors » Marie-Laure Plissonnier

Marie-Laure Plissonnier

Explore the profile of Marie-Laure Plissonnier including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 33
Citations 296
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hernandez C, Verzeroli C, Roca-Suarez A, Farca-Luna A, Tonon L, Esteban-Fabro R, et al.
JHEP Rep . 2024 Dec; 7(1):101245. PMID: 39717507
Background & Aims: Owing to unexplained interpatient variation and treatment failure in hepatocellular carcinoma (HCC), novel therapeutic approaches remain an urgent clinical need. Hepatic neurons, belonging to the autonomic nervous...
2.
Degasperi E, Scholtes C, Testoni B, Uceda Renteria S, Anolli M, Charre C, et al.
J Hepatol . 2024 Dec; PMID: 39662705
Background & Aims: Serum HBV RNA and hepatitis B core-related antigen (HBcrAg) levels have been proposed as useful biomarkers in the management of patients with HBV; however, their role in...
3.
Roca Suarez A, Plissonnier M, Michelet M, Dubois A, Heintz S, Saez-Palma M, et al.
STAR Protoc . 2024 Oct; 5(4):103359. PMID: 39368096
The liver microenvironment contains a wide variety of monocyte and macrophage populations. Here, we present a protocol for the specific isolation of liver-resident macrophages, known as Kupffer cells (KCs), from...
4.
Paturel A, Casuscelli di Tocco F, Bousquet D, Plissonnier M, Grand X, Tak H, et al.
JHEP Rep . 2024 Sep; 6(10):101124. PMID: 39328324
Background & Aims: Circulating HBV RNAs have been proposed as a biomarker that reflects the transcriptional activity of covalently closed circular DNA (cccDNA) and may help to evaluate HBV treatment...
5.
Ringelhan M, Schuehle S, van de Klundert M, Kotsiliti E, Plissonnier M, Faure-Dupuy S, et al.
JHEP Rep . 2024 Sep; 6(10):101128. PMID: 39290403
Background & Aims: Although most hepatocellular carcinoma (HCC) cases are driven by hepatitis and cirrhosis, a subset of patients with chronic hepatitis B develop HCC in the absence of advanced...
6.
Telouk P, Plissonnier M, Merle P, Zoulim F, Fares N, Guilloreau P, et al.
Gastro Hep Adv . 2024 Aug; 1(3):480-486. PMID: 39131686
Background And Aims: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide, and finding a single reliable biomarker to follow liver degradation is a challenging task. To...
7.
Roca Suarez A, Plissonnier M, Grand X, Michelet M, Giraud G, Saez-Palma M, et al.
Gut . 2024 May; 73(12):2012-2022. PMID: 38697771
Objective: Achieving HBV cure will require novel combination therapies of direct-acting antivirals and immunomodulatory agents. In this context, the toll-like receptor 8 (TLR8) agonist selgantolimod (SLGN) has been investigated in...
8.
Begre L, Boyd A, Plissonnier M, Testoni B, Salazar-Vizcaya L, Suter-Riniker F, et al.
J Infect Dis . 2024 Apr; 230(4):e954-e963. PMID: 38626170
Background: We evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core-related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during...
9.
Narmada B, Khakpoor A, Shirgaonkar N, Narayanan S, Aw P, Singh M, et al.
J Hepatol . 2024 Feb; 81(1):42-61. PMID: 38423478
Background & Aims: Hepatitis B surface antigen (HBsAg) loss or functional cure (FC) is considered the optimal therapeutic outcome for patients with chronic hepatitis B (CHB). However, the immune-pathological biomarkers...
10.
Testoni B, Scholtes C, Plissonnier M, Paturel A, Berby F, Facchetti F, et al.
Gut . 2023 Oct; 73(4):659-667. PMID: 37879886
Objective: A convenient, reproducible biomarker of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) transcriptional activity is lacking. We measured circulating HBV RNA (cirB-RNA) in untreated and nucleos(t)ide analogues...